Standigm Revenue and Competitors

Seoul,

Location

N/A

Total Funding

AI

Industry

Estimated Revenue & Valuation

  • Standigm's estimated annual revenue is currently $4.8M per year.(i)
  • Standigm's estimated revenue per employee is $112,000

Employee Data

  • Standigm has 43 Employees.(i)
  • Standigm grew their employee count by -9% last year.

Standigm's People

NameTitleEmail/Phone
1
CEO & Chairman, Co-founderReveal Email/Phone
2
VP Strategic AlliancesReveal Email/Phone
3
Senior Principal ScientistReveal Email/Phone
4
Principal ScientistReveal Email/Phone
5
Principal ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M4N/AN/AN/A
#2
$3.4M307%N/AN/A
#3
$27M17526%N/AN/A
#4
$7.7M610%N/AN/A
#5
$175.6M877-6%$91.2MN/A
#6
$1.5M18-5%N/AN/A
#7
$2M20N/AN/AN/A
#8
$0.2M3-70%N/AN/A
#9
$32M20841%N/AN/A
#10
$1.3M16-33%N/AN/A
Add Company

What Is Standigm?

Standigm is an AI-driven drug discovery company. Applying its own innovative AI to the real world, Standigm currently has more than 20 preclinical pipelines across various therapeutic areas. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactoryâ„¢, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASKâ„¢ for target discovery, Standigm BESTâ„¢ for lead selection, and Standigm Insightâ„¢ for drug repurposing. Founded in 2015, Standigm has raised $23M from leading investors and developed an elite team with multi-disciplinary expertise in chemistry, biology, pharmacology, artificial intelligence, and data structures to ease the pains of patients all over the world.

keywords:N/A

N/A

Total Funding

43

Number of Employees

$4.8M

Revenue (est)

-9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.1M44N/AN/A
#2
$5.3M46-2%N/A
#3
$5M4833%N/A
#4
$10.4M48-9%N/A
#5
$5.8M504%N/A